Verseon Corporation Transaction in Own Shares and Total Voting Rights (2391H)

TIDMVSN

RNS Number : 2391H

Verseon Corporation

06 June 2017

June 6, 2017

Verseon Corporation

("Verseon" or the "Company")

Transaction in Own Shares and Total Voting Rights

FREMONT, Calif.-Verseon, a technology-based pharmaceutical company, announces that on June 5, 2017 the Company purchased 42,917 Common Shares in the Company (the "Shares") for an aggregate price of $10,729.25 (the "Transaction") from former option holders in accordance with the terms and conditions of the Company's 2007 Option Plan (the "2007 Plan"). Following the Transaction, the Shares will be held in treasury.

Pursuant to the 2007 Plan, during their services to the Company, option holders may elect to exercise options prior to their full vesting, with the Company retaining the right to repurchase any unvested shares at the original purchase price at the completion of the option holders' service.

Total Voting Rights

Following the Transaction, the issued share capital of the Company will consist of 151,452,891 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 151,409,974. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact

 
 Verseon Corporation                www.verseon.com 
                                    +1 (510) 225 
 Tina Schlafly                       9000 
 
 Cenkos Securities (NOMAD and 
  Joint Broker) 
                                     +44 (0) 20 
 Neil McDonald / Beth McKiernan       7397 8900 
 
 Cantor Fitzgerald Europe (Joint 
  Broker) 
 Marc Milmo / Phil Davies /         +44 (0) 20 
  Callum Butterfield                 7894 7000 
 
 Mirabaud Securities LLP (Joint 
  Broker) 
                                    +44 (0) 20 
 Peter Krens                         7321 2508 
 

For financial and business media enquiries, please contact

 
 Buchanan Communications Ltd 
  (PR Advisers) 
 Henry Harrison-Topham / Jamie    +44 (0) 20 
  Hooper                           7466 5000 
 

For trade and pharma media enquiries, please contact

 
 Vane Percy & Roberts 
                         +44 (0) 1737 
 Simon Vane Percy         821 890 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUGUWUQUPMUMQ

(END) Dow Jones Newswires

June 06, 2017 03:15 ET (07:15 GMT)